Given that the β6-ERK2 interaction mediates MMP-9 secretion and that de novo expression of β6 occurs in epithelial cancer cells, inhibition of MMP activity by targetting either β6 or the ERK2 binding site may offer greater therapeutic specificity in cancer treatment than MMP inhibitors and avoid unwanted side effects. Here, MAPK1 is linked to cancer.